Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Pediatric Hematology/Oncology
•
Medical Oncology
•
Lymphoma
•
Hodgkin Lymphoma
•
AYA
How would you treat a young patient with advanced stage classical Hodgkin lymphoma with HIV?
Related Questions
In pediatric patients with Hodgkin lymphoma who have a partial response after chemotherapy and multiple disease sites above and below the diaphragm, how do you approach radiotherapy planning considering cumulative dose and toxicity?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?
How would you approach treatment with BV-CHP regimen in a patient with newly diagnosed CD30+ ALK- anaplastic large cell lymphoma at high risk for cardiotoxicity?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?
Do you still recommend consolidative allogeneic stem cell transplants for patients with Richter transformation in CR after frontline treatment in the modern era of therapies?
